Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Approvals/CIMA-AEMPS/BILASTINA TEVAGEN 20 MG COMPRIMIDOS EFG

Approved

STANDARD

BILASTINA TEVAGEN 20 MG COMPRIMIDOS EFG

Teva Pharma S.L.U.🇪🇸 Spanish Agency of Medicines and Medical Devices

Approval Date: Apr 19, 2021
Approval ID: 4c5a5afee6bc4020
Company: Teva Pharma S.L.U.
Type: Standard

Approval Details

Approval Id: 4c5a5afee6bc4020
Drug Cima Aemps Name: BILASTINA TEVAGEN 20 MG COMPRIMIDOS EFG
Register Number: 85922
Holder Company Name: Teva Pharma S.L.U.
Marketing Company Name: Teva Pharma S.L.U.
Authorization Date: 2021-04-19
Dosage Form: COMPRIMIDO
Dose: 20 mg
Route Of Administration: VÍA ORAL
Prescription Type: Sin Receta
Commercialized: Yes
Company Name: Teva Pharma S.L.U.

Active Ingredients

BILASTINA

20 mg

Approved

Quick Info

Agency

CIMA-AEMPS

Country

🇪🇸

Approval Date

Apr 19, 2021

Approval ID

4c5a5afee6bc4020

Type

Standard

Back to CIMA-AEMPS Approvals

BILASTINA TEVAGEN 20 MG COMPRIMIDOS EFG - CIMA-AEMPS Drug Approval Details